Collegium Pharmaceutical Inc
NASDAQ:COLL
Collegium Pharmaceutical Inc
NASDAQ:COLL
Price:
37.51 USD
Market Closed
Updated:
May 4, 2024
Collegium Pharmaceutical Inc
Operating Income
|
Collegium Pharmaceutical Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
Operating Income
$175.5m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Collegium Pharmaceutical Inc's Operating Income?
Operating Income
175.5m
USD
175.5m
USD
Based on the financial report for Dec 31, 2023, Collegium Pharmaceutical Inc's Operating Income amounts to 175.5m USD.
What is Collegium Pharmaceutical Inc's Operating Income growth rate?
Operating Income CAGR 3Y
46%
46%
Over the last year, the Operating Income growth was 153%. The average annual Operating Income growth rates for Collegium Pharmaceutical Inc have been 46% over the past three years .
You don't have any saved screeners yet
